Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Big Week For FDA’s Top Eye Drug Reviewer

Executive Summary

Ophthalmology supervisory medical officer Wiley Chambers played a key role at three different advisory committee meetings in early October. Only one was a review in his division.

Advertisement

Related Content

Semaglutide Retinopathy Risk No Bar To Approval, US Panel Says
Aerie's Netarsudil Headed For Broad Indication With Only Subpopulation Efficacy
How To Build An Endpoint: Spark Designed Testing Maze To Study Rare Vision Loss
Spark's Gene Therapy Luxturna Sails Through US FDA Panel

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121797

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel